The beginning of the end for serogroup B meningococcus?

The Lancet

Volumn 381, Issue 9869, 2013, Pages 785-787

  Snape, Matthew D ^a,b   Pollard, Andrew J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; MENINGITIS VACCINE; NEISSERIA MENINGITIDIS SEROGROUP B VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BACTERICIDAL ACTIVITY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEBRILE CONVULSION; HERD IMMUNITY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MENINGITIS; MENINGOCOCCOSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEISSERIA MENINGITIDIS; NONHUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM TEMPERATURE; SEPTICEMIA;

EID: 84874685108     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62194-1     Document Type: Note

References (12)

1. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010; 10: 112-24.
2. Vesikari T, Esposito S, Prymula R, et al, for the EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concurrently with routine infant and child vaccinations: results of two randomised trials. Lancet 2012; published online Jan 14. http://dx.doi.org/10.1016/S0140-6736(12)61961-8.
3. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307: 573-82.
4. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51: 1127-37.
5. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010; 29: e71-79.
6. European Medicines Agency. Summary of Opinion, Bexsero. 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002333/smops/Positive/human-smop-000447.jsp&mid= WC0b01ac058001d127 (accessed Dec 3, 2012).
7. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23: 2222-27.
8. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009; 38: 413-18.
9. Donnelly J, Medini D, Giuliani MM, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. 11th European Meningococcal Disease Society EMGM; Ljubljana, Slovenia; May 18-20, 2011: 17-18. http://emgm.eu/meetings/emgm2011/abstracts.pdf (accessed Jan 7, 2013).
10. Prymula R, Esposito S, Kittel C, Kohl I, Toneatto D, Dull P. Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunizations. 29th Annual Meeting of the European Society for Paediatric Infectious Diseases; The Hague, Netherlands; June 7-11, 2011. http://www.kenes.com/espid2011/cd/pdf/ P770.pdf (accessed Jan 7, 2013).
11. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 853-61.
12. Health Protection Agency. Invasive meningococcal B infections laboratory reports, England and Wales by age group and epidemiological year, 1998/99-2011/12. 2012. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/ 1317136088588 (accessed Nov 27, 2012).